1. Home
  2. VRAX vs GLTO Comparison

VRAX vs GLTO Comparison

Compare VRAX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • GLTO
  • Stock Information
  • Founded
  • VRAX 2013
  • GLTO 2011
  • Country
  • VRAX United Kingdom
  • GLTO Denmark
  • Employees
  • VRAX N/A
  • GLTO N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • GLTO Health Care
  • Exchange
  • VRAX Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • VRAX 7.3M
  • GLTO 6.5M
  • IPO Year
  • VRAX 2022
  • GLTO 2020
  • Fundamental
  • Price
  • VRAX $1.75
  • GLTO $5.10
  • Analyst Decision
  • VRAX
  • GLTO Buy
  • Analyst Count
  • VRAX 0
  • GLTO 1
  • Target Price
  • VRAX N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • VRAX 216.4K
  • GLTO 16.9K
  • Earning Date
  • VRAX 02-05-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • VRAX N/A
  • GLTO N/A
  • EPS Growth
  • VRAX N/A
  • GLTO N/A
  • EPS
  • VRAX N/A
  • GLTO N/A
  • Revenue
  • VRAX $84,872.00
  • GLTO N/A
  • Revenue This Year
  • VRAX $5,169.18
  • GLTO N/A
  • Revenue Next Year
  • VRAX $66.97
  • GLTO N/A
  • P/E Ratio
  • VRAX N/A
  • GLTO N/A
  • Revenue Growth
  • VRAX 7.03
  • GLTO N/A
  • 52 Week Low
  • VRAX $0.60
  • GLTO $4.40
  • 52 Week High
  • VRAX $9.00
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 41.64
  • GLTO 47.88
  • Support Level
  • VRAX $1.56
  • GLTO $4.70
  • Resistance Level
  • VRAX $1.85
  • GLTO $5.35
  • Average True Range (ATR)
  • VRAX 0.21
  • GLTO 0.39
  • MACD
  • VRAX -0.06
  • GLTO -0.01
  • Stochastic Oscillator
  • VRAX 25.64
  • GLTO 40.00

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: